MX2011007195A - Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih). - Google Patents

Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).

Info

Publication number
MX2011007195A
MX2011007195A MX2011007195A MX2011007195A MX2011007195A MX 2011007195 A MX2011007195 A MX 2011007195A MX 2011007195 A MX2011007195 A MX 2011007195A MX 2011007195 A MX2011007195 A MX 2011007195A MX 2011007195 A MX2011007195 A MX 2011007195A
Authority
MX
Mexico
Prior art keywords
hcv
treatment
hiv infection
cyclosporine derivative
cyclosporine
Prior art date
Application number
MX2011007195A
Other languages
English (en)
Inventor
Samuel Earl Hopkins
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of MX2011007195A publication Critical patent/MX2011007195A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente se proporciona dosis especificas de , o regímenes de dosificación para, usar SCY-635 en el tratamiento o prevención de enfermedades, en particular infección por virus de hepatitis C (VHC).
MX2011007195A 2009-01-07 2010-01-07 Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih). MX2011007195A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14306209P 2009-01-07 2009-01-07
US15602609P 2009-02-27 2009-02-27
PCT/US2010/020316 WO2010080874A1 (en) 2009-01-07 2010-01-07 Cyclosporine derivative for use in the treatment of hcv and hiv infection

Publications (1)

Publication Number Publication Date
MX2011007195A true MX2011007195A (es) 2013-07-12

Family

ID=42101315

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007195A MX2011007195A (es) 2009-01-07 2010-01-07 Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).

Country Status (13)

Country Link
US (1) US20100173837A1 (es)
EP (1) EP2385838A1 (es)
JP (1) JP2012514605A (es)
KR (1) KR20110116136A (es)
CN (1) CN102271699A (es)
AU (1) AU2010203656A1 (es)
CA (1) CA2750227A1 (es)
IL (1) IL213861A0 (es)
MX (1) MX2011007195A (es)
RU (1) RU2011127080A (es)
SG (1) SG172848A1 (es)
WO (1) WO2010080874A1 (es)
ZA (1) ZA201105343B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1802650T1 (sl) * 2004-10-01 2012-03-30 Scynexis Inc Eter in tioeter substituirani ciklosporinski derivati za zdravljenje in preventivo pred infekcijami s hepatitisom c
CA2623864C (en) * 2005-09-30 2014-12-16 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
EP2023918B1 (en) 2006-05-19 2011-03-23 Scynexis, Inc. Cyclosporins for the treatment and prevention of ocular disorders
KR101089112B1 (ko) * 2006-06-02 2011-12-06 피씨 제스띠옹 에스.아.에스. 활성 전자 관리
JP5820722B2 (ja) 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
CA2748389A1 (en) * 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
CN107007815A (zh) 2010-07-16 2017-08-04 美国科技环球有限公司 新颖的环孢霉素a衍生物在病毒感染的治疗和预防中的应用
WO2012021796A2 (en) 2010-08-12 2012-02-16 S&T Global, Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
AU2011336266B2 (en) * 2010-12-03 2017-04-06 S&T Global Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
US20120208746A1 (en) * 2011-01-12 2012-08-16 Scynexis Inc. Genetic markers associated with response to cyclophilin-binding compounds
MX2014002171A (es) * 2011-08-24 2014-04-25 Glaxosmithkline Llc Tratamientos de combinacion para hepatitis c.
SG11201807012QA (en) 2016-02-25 2018-09-27 Asceneuron S A Acid addition salts of piperazine derivatives
CN106554392B (zh) * 2016-11-21 2019-10-25 石家庄中天生物技术有限责任公司 一种高纯度环孢菌素衍生物stg-175的制备方法
WO2020118714A1 (en) * 2018-12-14 2020-06-18 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Maleate of scy-635 and uses thereof in medicine
US12226446B2 (en) * 2019-10-11 2025-02-18 Waterstone Pharmaceuticals(Wuhan) Co., Ltd. WS-635 uses thereof in medicine
IL309862A (en) * 2021-07-05 2024-02-01 Ferrer Int Medicines that include glycosidase inhibitors
WO2024158815A1 (en) * 2023-01-24 2024-08-02 The General Hospital Corporation Use of ws635 to treat alzheimer's disease

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
DK1003775T3 (da) 1997-08-11 2005-05-30 Boehringer Ingelheim Ca Ltd Hepatitis C-inhibitorpeptider
WO1999007734A2 (en) 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
ATE298317T1 (de) 1998-07-27 2005-07-15 Angeletti P Ist Richerche Bio Diketosäure-derivate als hemmstoffe von polymerasen
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
CA2363274A1 (en) 1999-12-27 2001-07-05 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs for hepatitis c
JP4748911B2 (ja) 2000-04-05 2011-08-17 シェーリング コーポレイション Ｎ−環状ｐ２部分を含むｃ型肝炎ウイルスの大環状ｎｓ３‐セリンプロテアーゼ阻害剤
CN1432022A (zh) 2000-04-19 2003-07-23 先灵公司 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3－丝氨酸蛋白酶抑制剂
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
CZ303213B6 (cs) 2000-07-21 2012-05-23 Schering Corporation Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostredek
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
RU2003105221A (ru) 2000-07-21 2004-09-20 Шеринг Корпорейшн (US) Новые пептиды, как ингибиторы ns3-серинпротеазы вируса гепатита с
CA2429359A1 (en) 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
CN1301994C (zh) 2000-12-12 2007-02-28 先灵公司 作为c型肝炎病毒ns3－丝氨酸蛋白酶抑制剂的二芳基肽
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
WO2003026587A2 (en) 2001-09-26 2003-04-03 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
GB0201179D0 (en) 2002-01-18 2002-03-06 Angeletti P Ist Richerche Bio Therapeutic agents
NZ533861A (en) 2002-01-23 2006-03-31 Schering Corp Proline compounds as NS3-serine protease inhibitors for use in treatment of hepatitis C virus infection
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
DE60334205D1 (en) 2002-05-20 2010-10-28 Bristol Myers Squibb Co Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
PL213029B1 (pl) 2002-05-20 2012-12-31 Bristol Myers Squibb Co Podstawiona pochodna cykloalkilowa, zawierajaca ja kompozycja oraz ich zastosowanie
EP1506172B1 (en) 2002-05-20 2011-03-30 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20040138109A1 (en) 2002-09-30 2004-07-15 Boehringer Ingelheim Pharmaceuticals, Inc. Potent inhibitor of HCV serine protease
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US20050159345A1 (en) 2002-10-29 2005-07-21 Boehringer Ingelheim International Gmbh Composition for the treatment of infection by Flaviviridae viruses
PL376823A1 (pl) 2002-11-01 2006-01-09 Abbott Laboratories Środki przeciwzakaźne
US7902203B2 (en) 2002-11-01 2011-03-08 Abbott Laboratories, Inc. Anti-infective agents
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2004072243A2 (en) 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
EP1601685A1 (en) 2003-03-05 2005-12-07 Boehringer Ingelheim International GmbH Hepatitis c inhibiting compounds
JP4682140B2 (ja) 2003-03-05 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類縁体
GB0307891D0 (en) 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
EP1629000B1 (en) 2003-04-16 2009-02-18 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
AU2004231987C1 (en) 2003-04-18 2010-09-30 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
CA2522577C (en) 2003-05-21 2011-04-26 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
WO2004113365A2 (en) 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
GB0313250D0 (en) 2003-06-09 2003-07-16 Angeletti P Ist Richerche Bio Therapeutic agents
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
BRPI0413234A (pt) 2003-08-01 2006-10-03 Genelabs Tech Inc derivados de imidazola bicìclica contra flaviviridae
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
WO2005019191A2 (en) 2003-08-25 2005-03-03 Abbott Laboratories 1, 1-dioxido-4h-1,2,4-benzothiadiazine derivate und verwandte verbindungen als inhibitoren der hcv polymerase zur behandlung von hepatitis c
US7378414B2 (en) 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
CA2536570A1 (en) 2003-08-26 2005-03-10 Schering Corporation Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
WO2005021568A2 (en) 2003-08-27 2005-03-10 Biota, Inc. Novel tricyclic nucleosides or nucleotides as therapeutic agents
GB0321003D0 (en) 2003-09-09 2003-10-08 Angeletti P Ist Richerche Bio Compounds, compositions and uses
US7112601B2 (en) 2003-09-11 2006-09-26 Bristol-Myers Squibb Company Cycloalkyl heterocycles for treating hepatitis C virus
UY28525A1 (es) 2003-09-22 2005-04-29 Boehringer Ingelheim Int Péptidos macrociclicos activos contra en virus de la hepatitis c
BRPI0414814A (pt) 2003-09-26 2006-11-14 Schering Corp inibidores macrocìclicos de protease de serina ns3 de vìrus de hepatite c
GB0323845D0 (en) 2003-10-10 2003-11-12 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
HRP20130098T1 (hr) 2003-10-14 2013-02-28 F. Hoffmann - La Roche Ag MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a
US20050119318A1 (en) 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2005049622A1 (ja) 2003-11-19 2005-06-02 Japan Tobacco Inc. ５－５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
CN1902216A (zh) 2003-11-20 2007-01-24 先灵公司 丙肝病毒ns3蛋白酶的去肽化抑制剂
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
TW200518746A (en) 2003-12-11 2005-06-16 Schering Corp Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
CA2549851C (en) 2004-01-21 2012-09-11 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
TWI368507B (en) 2004-02-20 2012-07-21 Boehringer Ingelheim Int Viral polymerase inhibitors
ATE428714T1 (de) 2004-02-24 2009-05-15 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
EP1737881B1 (en) 2004-02-27 2009-06-24 Schering Corporation Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2005085242A1 (en) 2004-02-27 2005-09-15 Schering Corporation Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
ES2328589T3 (es) 2004-02-27 2009-11-16 Schering Corporation Compuestos de la prolina 3,4(ciclopentil) fusionados como inhibidores de la proteasa serina ns3 del virus de la hepatitis c.
EP1730165A1 (en) 2004-02-27 2006-12-13 Schering Corporation Inhibitors of hepatitis c virus ns3 protease
JP2007525521A (ja) 2004-02-27 2007-09-06 シェーリング　コーポレイション Ｃ型肝炎ウイルスｎｓ３セリンプロテアーゼのインヒビターとしてのシクロブテンジオン基含有化合物
CN1946691A (zh) 2004-02-27 2007-04-11 先灵公司 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的化合物
BRPI0508085A (pt) 2004-02-27 2007-07-17 Schering Corp compostos de enxofre como inibidores da ns3 serina protease do vìrus da hepatite c
PE20060309A1 (es) 2004-05-06 2006-04-13 Schering Corp (1r,2s,5s)-n-[(1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil]-3-[(2s)-2[[[(1,1-dimetiletil)amino]carbonil]amino]-3,3-dimetil-1-oxobutil]-6,6-dimetil-3-azabiciclo[3.1.o]hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de l
DE602005015452D1 (de) 2004-05-20 2009-08-27 Schering Corp Substituierte proline als hemmer der ns3-serinprotease des hepatits-c-virus
WO2005121132A1 (ja) 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗ｈｃｖ作用を有する縮合ヘテロ環化合物
GB0413087D0 (en) 2004-06-11 2004-07-14 Angeletti P Ist Richerche Bio Therapeutic compounds
EP1763531A4 (en) 2004-06-28 2009-07-01 Boehringer Ingelheim Int ANALOGUE OF HEPATITIS-C INHIBITING PEPTIDES
UY29017A1 (es) 2004-07-16 2006-02-24 Boehringer Ingelheim Int Inhibidores de polimerasa viral
ES2366478T3 (es) 2004-07-20 2011-10-20 Boehringer Ingelheim International Gmbh Análogos peptídicos inhibidores de la hepatitis c.
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
GB0416396D0 (en) 2004-07-22 2004-08-25 Angeletti P Ist Richerche Bio Therapeutic agents
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
GB0419850D0 (en) 2004-09-07 2004-10-13 Angeletti P Ist Richerche Bio Therapeutic agents
SI1802650T1 (sl) * 2004-10-01 2012-03-30 Scynexis Inc Eter in tioeter substituirani ciklosporinski derivati za zdravljenje in preventivo pred infekcijami s hepatitisom c
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
JP2008517896A (ja) 2004-10-21 2008-05-29 ファイザー・インク Ｃ型肝炎ウイルスプロテアーゼの阻害剤並びにそれを用いた組成物及び治療
EP1807397A2 (en) 2004-10-26 2007-07-18 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Tetracyclic indole derivatives as antiviral agents
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
WO2006093801A1 (en) 2005-02-25 2006-09-08 Abbott Laboratories Thiadiazine derivatives useful as anti-infective agents
US8802840B2 (en) 2005-03-08 2014-08-12 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
GB0509326D0 (en) 2005-05-09 2005-06-15 Angeletti P Ist Richerche Bio Therapeutic compounds
US7569600B2 (en) 2005-05-13 2009-08-04 Virochem Pharma Inc. Compounds and methods for the treatment of prevention of Flavivirus infections
US20080200497A1 (en) 2005-07-20 2008-08-21 Bailey Murray D Hepatitis C Inhibitor Peptide Analogs
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
EP1913016B1 (en) 2005-08-01 2013-01-16 Merck Sharp & Dohme Corp. Macrocyclic peptides as hcv ns3 protease inhibitors
CA2618682C (en) 2005-08-12 2011-06-21 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2007028789A1 (en) 2005-09-07 2007-03-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Quinazoline derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
AU2005336627A1 (en) 2005-09-19 2007-03-29 Arrow Therapeutics Limited Benzodiazepine derivatives for treating hepatitis C infection
WO2007039146A1 (en) 2005-09-23 2007-04-12 Smithkline Beecham Corporation 4-carboxy pyrazole derivatives as anti-viral agents
GB0522881D0 (en) 2005-11-10 2005-12-21 Angeletti P Ist Richerche Bio Therapeutic compounds
ITRM20050611A1 (it) 2005-12-06 2007-06-07 Angeletti P Ist Richerche Bio Derivati azanucleosidici ad attivita' antivirale.
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2007092000A1 (en) 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Inhibitors of hcv replication
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
JP2009526850A (ja) 2006-02-14 2009-07-23 メルク エンド カムパニー インコーポレーテッド Ｒｎａ依存性ｒｎａウイルス感染を治療するためのヌクレオシドアリールホスホルアミデート
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521442B2 (en) 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
DE602007006796D1 (de) 2006-05-25 2010-07-08 Bristol Myers Squibb Co Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

Also Published As

Publication number Publication date
EP2385838A1 (en) 2011-11-16
CN102271699A (zh) 2011-12-07
SG172848A1 (en) 2011-08-29
AU2010203656A2 (en) 2011-09-08
US20100173837A1 (en) 2010-07-08
JP2012514605A (ja) 2012-06-28
WO2010080874A1 (en) 2010-07-15
AU2010203656A1 (en) 2011-07-21
ZA201105343B (en) 2012-03-28
IL213861A0 (en) 2011-07-31
RU2011127080A (ru) 2013-02-20
KR20110116136A (ko) 2011-10-25
CA2750227A1 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
MX2011007195A (es) Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
MD20140058A2 (en) Compositions and methods for treating hepatitis C virus
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
MY202109A (en) Viral replication inhibitors
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
EA201301158A1 (ru) Противовирусные соединения
WO2017027350A3 (en) Rnai therapy for hepatitis b virus infection
IL195025A (en) History of compressed indolubenzazepine with cyclopropyl and pharmaceuticals containing them as an anti-hcv drug
MX350725B (es) Fosforamidatos de nucleosido.
NZ737757A (en) Peptide oligonucleotide conjugates
PH12014500557A1 (en) Methods for treating hcv
MX2011007364A (es) Derivados de fosforamidato de compuestos de nuecleosido de guanosina para tratamiento de infecciones virales.
EA201201235A1 (ru) Комбинации фармацевтических агентов в качестве ингибиторов репликации hcv
PH12014500833A1 (en) Methods for treating hcv
MX2011008045A (es) Inhibidores del virus de la hepatitis c.
MY152971A (en) Hepatitis c virus inhibitors
MY201105A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
MX2016004492A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana (vih).
MY194294A (en) Novel viral replication inhibitors
MX2013001237A (es) Compuestos inhibidores del virus de la hepatitis c.
ZA201403852B (en) Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection
PH12014500385A1 (en) Benzofuran compounds for the treatment of hepatitis c virus infections
PH12014500283A1 (en) Hcv immunotherapy
EA201590297A1 (ru) Гетероциклические карбоксамиды для лечения вирусных заболеваний
MX2013003903A (es) Nuevos tratamientos de infeccion por el virus de hepatitis c.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal